echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Pfizer/BioNTech's COVID-19 vaccine Comirnaty: Postponing decision on whether to vaccinate children under 5

    Pfizer/BioNTech's COVID-19 vaccine Comirnaty: Postponing decision on whether to vaccinate children under 5

    • Last Update: 2022-03-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pfizer and BioNTech said on Friday that they are awaiting FDA approval for the COVID-19 vaccine Comirnaty for children under 5
    .


    An FDA advisory panel meeting scheduled for February 15 to discuss the application was also postponed


    FDA COVID-19 Children

    At the FDA's request, Pfizer/BioNTech began rolling submissions to expand Comirnaty's Emergency Use Authorization (EUA) to include children 6 months to under 5 years of age
    .


    The companies said at the time that results from the Phase II/III study on the third injection would be available at least eight weeks after the second, with specific trial data expected in the coming months


    At the FDA's request, Pfizer/BioNTech began rolling submissions to expand Comirnaty's Emergency Use Authorization (EUA) to include children 6 months to under 5 years of age


    On Friday, Pfizer and BioNTech said, "Given the rapid progress in this study, we will await three-dose data as we continue to believe that it may provide a higher level of protection in this age group
    .


    Given the prevalence of children in this age group Infection rates remain high, especially due to the recent surge in Omicron cases, and there is an urgent need to know Comirnaty's protective effect on children


    Infect

    Comirnaty is an mRNA vaccine that utilizes copies of a molecule called messenger RNA (mRNA) to generate an immune response to the vaccine
    .


    Such vaccines deliver antigen-encoding mRNA molecules into immune cells, which use the designed mRNA as a template to synthesize the foreign proteins of the COVID-19 virus


    Immune management

     

    Original source:

    Original source:

    https://firstwordpharma.


    https://firstwordpharma.
    com/story/5498095 https://firstwordpharma.
    com/story/5498095 Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.